Page 6 - Brian Goff News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.51) EPS for the quarter, topping the consensus estimate of ($1.60) by $0.09, Briefing.com reports. Agios Pharmaceuticals had a negative return on equity of 19.77% and a negative net margin of 1,042.56%. The business had revenue of […]

Agios Pharmaceuticals has signed a license agreement with Alnylam Pharmaceuticals for preclinical Small interfering RNA (siRNA) development candidate.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2023 Earnings Call Transcript August 3, 2023 Agios Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.51 EPS, expectations were $1.6. Operator: Good morning, and welcome to Agios’ Second Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session […]

Operator: Good morning, and welcome to Agios’ Second Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end.

03.08.2023 - – Preclinical siRNA Targeting TMPRSS6 is a Potential Disease-Modifying Treatment for Polycythemia Vera – – Agreement Combines Agios’ Scientific Expertise and Capabilities in Rare Hematologic Diseases with Alnylam’s Industry-Leading siRNA Platform – ... Seite 1